Welcome to our dedicated page for Integer Hldgs SEC filings (Ticker: ITGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Device engineers know that building a pacemaker lead is painstaking; reading the filings of the company that makes it can be just as exacting. Integer Holdings’ 10-K spans intricate disclosures on cardiac rhythm management, neuromodulation, and sterile manufacturing lines, creating a maze for anyone hunting key numbers or insider moves. If you have ever typed “Integer Holdings SEC filings explained simply” or wanted the cardiac segment margin without scrolling through 250 pages, you have felt the problem.
Stock Titan delivers the solution. Our platform ingests every submission the moment it hits EDGAR and converts legal jargon into plain language with AI-powered summaries. Want “Integer Holdings quarterly earnings report 10-Q filing” insights? Need “Integer Holdings insider trading Form 4 transactions” in real time? Looking for the specific 8-K that details a new sterilization line? Find them fast, plus concise explanations of why they matter. Key sections are surfaced automatically so you can:
- Track “Integer Holdings executive stock transactions Form 4” before material events
- Compare backlog growth across divisions using “Integer Holdings earnings report filing analysis”
- Spot pay structures in the “Integer Holdings proxy statement executive compensation”
Whether you are understanding Integer Holdings SEC documents with AI for compliance checks or modelling forecasts, every 10-K, 10-Q, 8-K material event, and “Integer Holdings annual report 10-K simplified” summary is here—updated continuously, searchable instantly, and interpreted clearly. Save hours, avoid missed details, and make confident decisions with the only page that links Integer’s precision manufacturing story to the numbers behind it.
Integer Holdings director Martin C. Maxwell reported stock-based transactions. On 12/12/2025 he exercised stock options for 2,883 shares of common stock at an exercise price of $48.43 per share, temporarily increasing his direct holdings to 25,053 shares. On the same date, 1,914 shares were withheld by the company at $72.975 per share to satisfy the stock option exercise price, leaving him with 23,139 shares held directly after the transactions. The non-qualified stock options exercised covered 2,883 underlying shares, carried a $48.43 exercise price, vested 25% on the first day of each fiscal quarter in 2016, and are now fully exercised with no remaining derivative securities reported.
Integer Holdings Corp (ITGR) executive John A. Harris reported an open-market purchase of company stock. On 11/12/2025, he bought 1,650 shares of common stock at $70 per share (Transaction Code P).
Following the transaction, his directly held beneficial ownership stands at 6,066 shares. The filing lists his role as EVP, Global Ops and Manufacturing and indicates direct (D) ownership.
Integer Holdings Corp (ITGR) officer Tommy P. Thomas reported an open-market sale of 884 shares of common stock at $70.15 per share on 11/11/2025, according to a Form 4 filing.
Following the transaction, Thomas beneficially owns 3,596 shares, held directly. His position is listed as VP, Corporate Controller. The filing was signed by attorney-in-fact Mark Zawodzinski on 11/13/2025.
Integer Holdings (ITGR) insider purchase: EVP and Chief Financial Officer acquired 1,115.83 shares of common stock on 11/07/2025 at a weighted average price of $67.185. Following the transaction, direct holdings total 7,697.83 shares.
The filing notes the purchase was executed across multiple trades with prices ranging from $67.1715 to $67.185, and the reporting person will provide detailed trade breakdowns upon request.
Integer Holdings Corp (ITGR) reported an insider purchase by director Cheryl C. Capps. On 11/06/2025, she bought 1,600 shares of common stock at $66.7 per share. Following the transaction, she beneficially owns 11,702 shares, held directly. The filing indicates it was submitted by one reporting person.
Integer Holdings Corporation announced a share repurchase program authorizing the Company to buy back up to $200,000,000 of its common stock. The board approved the program on November 3, 2025, with no expiration date, allowing repurchases to occur over time at management’s discretion.
Repurchases may be made on the open market, in privately negotiated transactions, or through trading plans or other arrangements. The program does not obligate the Company to repurchase any specific amount, and it can be suspended or terminated.
Integer Holdings (ITGR) reported an insider purchase by its President & CEO and Director, Payman Khales. On 10/30/2025, he bought 3,127 shares of common stock at a weighted average price of $64.94, with trade prices ranging from $64.7805 to $64.94. Following the transaction, he directly beneficially owns 22,865 shares.
Integer Holdings Corp (ITGR) filed a Form 4 reporting an equity award to its President & CEO, Payman Khales. On 10/24/2025, the reporting person was granted 7,543 restricted stock units (RSUs) under Transaction Code A.
The RSUs convert into common stock on a one-for-one basis and will vest in three equal annual installments beginning 10/24/2026. The filing lists the price as $0 and the ownership form as Direct (D).
Integer Holdings Corporation appointed Payman Khales to its Board and as President and Chief Executive Officer, effective
The company entered into a new Employment Agreement with Mr. Khales on
Integer Holdings (ITGR) filed a 10‑Q/A (Amendment No. 1) for the quarter ended September 26, 2025 to add context to MD&A. The amendment incorporates narrative from the October 23, 2025 earnings call about sales outlook and new product adoption expected to affect the next three fiscal quarters. No changes were made to the financial statements.
For Q3 2025, sales were $467.7 million and income from continuing operations was $39.7 million ($1.11 diluted EPS). Year‑to‑date, sales were $1.382 billion with $54.2 million of income from continuing operations ($1.52 diluted EPS). Cardio & Vascular sales rose 15% in Q3, aided by contributions from the Precision and VSi acquisitions.
Management updated its sales outlook to reflect lower‑than‑anticipated demand from select emerging customers and expects 2026 declines in three new products (two electrophysiology, one neuromodulation). In March 2025, the company issued $1.0 billion of 1.875% 2030 convertible notes (net
FAQ
What is the current stock price of Integer Hldgs (ITGR)?
What is the market cap of Integer Hldgs (ITGR)?
